文献速递心血管US

应用加速-射血时间比值对未分化矛盾性低流量低梯度主动脉瓣狭窄进行预后判断和介入指导

Prognostication and Interventional Guidance Using Acceleration-Ejection Time Ratio in Undifferentiated Paradoxical Low-Flow Low-Gradient Aortic Stenosis.
PubMed 文献 · JACC Cardiovasc Imaging · 2024-08-14

研究纳入171例超声心动图诊断为矛盾性低流量低梯度主动脉瓣狭窄(PLFAS)患者,按AT:ET截断值0.35分组,中位随访8.9年。AT:ET≥0.35是主要结局的独立预测因子(HR 4.77),且该组行主动脉瓣置换与5年心脏死亡和全因死亡显著降低相关,而AT:ET<0.35组未见生存获益。

要点

  • AT:ET≥0.35是PLFAS患者5年心脏死亡或AVR复合结局的独立预测因子(HR 4.77)。
  • AT:ET≥0.35组行AVR与5年心脏死亡(HR 0.09)和全因死亡(HR 0.16)显著降低相关。
  • AT:ET<0.35组行AVR未显示生存改善。

核心结论

  • 在未分化PLFAS患者中,AT:ET≥0.35预测更差结局和/或需要AVR,AT:ET可能有助于改善预后性AVR的患者选择。

研究设计与样本

  • 研究为队列研究,纳入171例超声心动图诊断为PLFAS的患者,按AT:ET截断值0.35分组,中位随访8.9年。

诊断标准与关键数值

  • PLFAS定义:主动脉瓣面积<1.0 cm²或指数化主动脉瓣面积<0.6 cm²/m²,平均压差<40 mm Hg,指数化每搏输出量<35 mL/m²,左心室射血分数≥50%。
  • AT:ET≥0.35预测主要结局的HR为4.77(95%CI 2.94-7.75),P<0.001。
  • AT:ET≥0.35预测心脏死亡的HR为2.91(95%CI 1.47-5.76),P=0.002;预测AVR的HR为8.45(95%CI 4.16-17.1),P<0.001。
  • AT:ET≥0.35组行AVR与5年心脏死亡(HR 0.09,95%CI 0.02-0.36,P<0.001)和全因死亡(HR 0.16,95%CI 0.07-0.38,P<0.001)降低相关。
  • AT:ET<0.35组行AVR未显示生存改善。

临床应用与阅片要点

  • 在未分化PLFAS患者中,AT:ET可能有助于识别从AVR获益的患者。
  • AT:ET≥0.35提示预后较差和/或需要AVR。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Studies in paradoxical low-flow low-gradient aortic stenosis (PLFAS) have demonstrated conflicting outcomes with variable survival advantage from aortic valve replacement (AVR). PLFAS is a heterogeneous composition of patients with uncertainty regarding true stenosis severity that continues to confound decision-making for AVR.

OBJECTIVES: The purpose of this study was to investigate the utility of the Doppler acceleration (AT) to ejection (ET) time ratio (AT:ET) for prediction of prognosis and benefit from AVR in undifferentiated PLFAS.

METHODS: Patients with echocardiographic findings of PLFAS (aortic valve area <1.0 cm2 or indexed aortic valve area <0.6 cm2/m2, mean gradient <40 mm Hg, indexed stroke volume <35 mL/m2, and left ventricular ejection fraction ≥50%) were identified and grouped according to an AT:ET cutoff of 0.35. The primary outcome was a 5-year composite of cardiac mortality or AVR. Secondary outcomes included the individual components of the primary endpoint and all-cause mortality at 5 years. Effect of AVR was analyzed in the AT:ET <0.35 and ≥0.35 groups.

RESULTS: A total of 171 PLFAS patients (median age 77.0 years, 57% women) were followed for a median of 8.9 years. AT:ET ≥0.35 was an independent predictor of the primary outcome (HR: 4.77 [95% CI: 2.94-7.75]; P < 0.001) with incremental value over standard indices of stenosis severity (net reclassification improvement: 0.57 [95% CI: 0.14-0.84]). AT:ET ≥0.35 also remained predictive of increased cardiac death (HR: 2.91 [95% CI: 1.47-5.76]; P = 0.002) and AVR (HR: 8.45 [95% CI: 4.16-17.1]; P < 0.001), respectively, following competing risk analysis. No difference in all-cause mortality was observed. AVR in the AT:ET ≥0.35 group was associated with significant reductions in 5-year cardiac (HR: 0.09 [95% CI: 0.02-0.36]; P < 0.001) and all-cause mortality (HR: 0.16 [95% CI: 0.07-0.38]; P < 0.001). No improvement in survival from AVR was demonstrated in AT:ET <0.35 patients.

CONCLUSIONS: AT:ET ≥0.35 in PLFAS predicts poorer outcomes and/or need for AVR. In undifferentiated PLFAS patients, AT:ET may have a potential role in improving patient selection for prognostic AVR.

来源:JACC Cardiovasc Imaging,查看原文。版权归原作者所有。

引用

  1. Chong A, Sen J, Reyaldeen R, et al. Prognostication and Interventional Guidance Using Acceleration-Ejection Time Ratio in Undifferentiated Paradoxical Low-Flow Low-Gradient Aortic Stenosis. JACC Cardiovasc Imaging. 2024. PMID: 39152958. doi:10.1016/j.jcmg.2024.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。